Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication
about
Anti-IL-12/23p40 antibodies for induction of remission in Crohn's diseaseProfile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease.Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapyInterferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding studyThe pathogenic potential of Campylobacter concisus strains associated with chronic intestinal diseases.Peripheral Blood CD64 Levels Decrease in Crohn's Disease following Granulocyte and Monocyte Adsorptive ApheresisReduced intracellular T-helper 1 interferon-gamma in blood of newly diagnosed children with Crohn's disease and age-related changes in Th1/Th2 cytokine profilesDistinct compartmentalization of NF-κB activity in crypt and crypt-denuded lamina propria precedes and accompanies hyperplasia and/or colitis following bacterial infectionIdentification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study.Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.Evidence of functional cross talk between the Notch and NF-κB pathways in nonneoplastic hyperproliferating colonic epithelium.Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues.Role of bacteria in the etiopathogenesis of inflammatory bowel diseaseInnate and adaptive mechanisms to control [corrected] pathological intestinal inflammation.Effect of Cyperus Rotundus on Cytokine Gene Expression in Experimental Inflammatory Bowel Disease.Systems biology coupled with label-free high-throughput detection as a novel approach for diagnosis of chronic obstructive pulmonary disease.Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.The use of ustekinumab in autoimmune disease.Cellular and molecular mechanisms in the two major forms of inflammatory bowel disease.Cytokine blockade in inflammatory bowel diseases.Review article: intestinal lymphoid nodular hyperplasia in children--the relationship to food hypersensitivity.Changes of the cytokine profile in inflammatory bowel diseases.Novel targets for inflammatory bowel disease therapeutics.New targeting strategies in drug therapy of inflammatory bowel disease: mechanistic approaches and opportunities.Novel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease.Targeted delivery systems for biological therapies of inflammatory diseases.Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events.Patients with Refractory Crohn's Disease Successfully Treated with Ustekinumab.Positioning ustekinumab in Crohn's disease: from clinical evidence to clinical practice.Circulating levels of interleukin (IL)-12 and IL-13 in Helicobacter pylori-infected patients, and their associations with bacterial CagA and VacA virulence factors.Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease.Inflammatory gene expression profiles in Crohn's disease and ulcerative colitis: a comparative analysis using a reverse transcriptase multiplex ligation-dependent probe amplification protocol.The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews.NOD2 stimulation by Staphylococcus aureus-derived peptidoglycan is boosted by Toll-like receptor 2 costimulation with lipoproteins in dendritic cells.Gut homeostasis and regulatory T cell induction depend on molecular chaperone gp96 in CD11c+ cells.Members of the novel UBASH3/STS/TULA family of cellular regulators suppress T-cell-driven inflammatory responses in vivo.Intestinal Barrier Interactions with Specialized CD8 T Cells.Remission of CVB3-induced viral myocarditis by in vivo Th2 polarization via hydrodynamics-based interleukin-4 gene transfer.Human intestinal mucosa-associated Lactobacillus and Bifidobacterium strains with probiotic properties modulate IL-10, IL-6 and IL-12 gene expression in THP-1 cells.Simvastatin attenuates trinitrobenzene sulfonic acid-induced colitis, but not oxazalone-induced colitis.
P2860
Q24188040-553A9037-F9CC-451E-91F6-4983EB461315Q26825174-BA033264-7D10-4B2B-BE9E-FD7908FDCD95Q28067631-1C71A42B-B4DF-4172-AA43-E165952FE031Q33420096-75A8E013-D5A6-4CA3-B36F-B7EA57AC327EQ34110695-9B7994A0-A0A0-4754-81EB-7B95BC702C33Q35649449-91150E12-AD2B-4852-8BB3-66DE2FD6A425Q35654647-C81FC211-7B9D-4FC9-B207-3878A2B97ACFQ35689452-4F3E44DA-634C-429F-A812-4EB872C9C320Q35877841-1EDF9DF1-BA05-400E-A279-CAAACA346438Q36203845-25C1618E-AECC-4687-8AAB-12A0AA648961Q36593483-02205169-AC37-49D1-94D6-4D99F54951CDQ36803301-9461C2B7-3167-41F0-96B6-67DCC104E7C3Q36975929-EE545291-25F0-41F5-AE3A-B76DA8C402C2Q37045757-8BAC7D53-C044-494F-9594-D99DC1F57AAEQ37140264-284E0447-3158-46FD-972B-344F9CD81F7AQ37182109-D316224B-3DA8-4B1D-9324-2BEFC81CA9A9Q37675050-80EE4882-4D9C-4268-9501-DC862652FB0FQ37706606-77179494-F753-4EB3-9272-2789C6582A12Q37890928-230E9798-2916-4F8F-AD74-89FEE830BB9CQ37952792-423F3CCE-D84E-41B0-A427-A98212795D64Q37994719-28D0F51F-847B-479A-A78F-C51405494025Q38058782-B9A77B3D-A0CE-4F13-864C-7180169B9246Q38073657-FBA453E0-4BE2-4074-BB35-54DA02D1B5CAQ38110619-10A15300-1F73-44C5-8512-38CF568AD3D1Q38253844-328CD047-539B-45AD-8A8F-17A7B7211952Q38264691-E8AB7DBC-9286-40F1-B19A-B278BE5BACA2Q38394816-BFEF6CA7-60C4-4ED9-A23A-2D8B8ABE3A34Q38692257-BF47991F-4AAE-4AD8-855D-9681E6714CD7Q38748380-07B96804-A74F-40CC-AF0D-8ABEF49356C4Q38995162-6CE1DD65-5772-42C5-879B-630D967A0421Q39249504-FAC0C956-3E18-4E25-A72D-554AC2113490Q39546806-2F2F2DCB-945B-44B7-B9FF-EDC6EDE17DE8Q39681190-52077564-DF3C-40D6-B43A-B15F1AD34525Q42058394-27E5FFCF-94A0-4DA7-99D6-422E9CC0FECDQ42254907-2D4C67BF-EB74-4FA5-9A9B-153A52DF30ACQ42673182-2C0EA4C9-48A1-4D1A-8624-6EC065AD70DAQ42700216-B257E672-AD18-4E97-8379-4B9A7A666EADQ45146937-FE581A29-2CA8-41A5-BF83-59534A13654DQ46815152-B1DBCDE1-C17E-4B4F-8EEF-2D8BAC565837Q46873746-4AEE9F99-DF17-4525-A4E1-8620A2D08538
P2860
Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Interleukin-12 and Th1 immune ...... ce and therapeutic implication
@ast
Interleukin-12 and Th1 immune ...... ce and therapeutic implication
@en
Interleukin-12 and Th1 immune ...... ce and therapeutic implication
@nl
type
label
Interleukin-12 and Th1 immune ...... ce and therapeutic implication
@ast
Interleukin-12 and Th1 immune ...... ce and therapeutic implication
@en
Interleukin-12 and Th1 immune ...... ce and therapeutic implication
@nl
prefLabel
Interleukin-12 and Th1 immune ...... ce and therapeutic implication
@ast
Interleukin-12 and Th1 immune ...... ce and therapeutic implication
@en
Interleukin-12 and Th1 immune ...... ce and therapeutic implication
@nl
P2860
P921
P356
P1476
Interleukin-12 and Th1 immune ...... ce and therapeutic implication
@en
P2093
Francesco Pallone
Giovanni Monteleone
P2860
P304
P356
10.3748/WJG.V12.I35.5606
P407
P577
2006-09-01T00:00:00Z